Precede Biosciences: Funding, Investors & Team (Sep 2026)
Precede Biosciences is revolutionizing precision medicine by redefining the knowledge that can be extracted from a basic blood sample. The company's goal is to enhance the probability of successful drug development while fostering a future where every patient can swiftly receive a personalized diagnosis and treatment that aligns with the specific biology of their ailment.
Precede Biosciences has raised $121M across 2 funding rounds on record, the most recent a Series B of $63.5M announced in Jan 2026.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Precede Biosciences Company Profile and Key Stats
Latest funding round on record: Jan 2026.
Precede Biosciences Funding Rounds
Precede Biosciences raised $57.0M in a Series A announced in Oct 2023.
2.3 years later, a Series B of $63.5M was announced in Jan 2026.
Precede Biosciences Founders and Leadership Team
No contact details are on record for this team yet.
Precede Biosciences Funding Compared to Other Biotechnology Startups
Precede Biosciences' latest round of $63.5M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Precede Biosciences in Biotechnology and Boston
Companies Similar to Precede Biosciences
Superluminal Medicines is a biotech company that specializes in rapidly developing new drugs through a…
Senticell's mission is to fully harness the unique immune and genetic functions of RBC to transform and treat…
ImmunoPhotonics, Inc. develops immunotherapy-based treatments for cancer. ImmunoPhotonics, Inc. has a…
EIT Pharma is a commercial-stage biotechnology company focuses on developing and commercializing…
Halia Therapeutics is a biopharmaceutical company in the preclinical stage that is developing new treatments…
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Precede Biosciences Funding FAQs
What does Precede Biosciences do?
Precede Biosciences is revolutionizing precision medicine by redefining the knowledge that can be extracted from a basic blood sample. The company's goal is to enhance the probability of successful drug development while fostering a future where every patient can swiftly receive a personalized diagnosis and treatment that aligns with the specific biology of their ailment.
How much funding has Precede Biosciences raised?
Precede Biosciences has raised $121M across 2 rounds on record. The most recent is a Series B of $63.5M announced in Jan 2026.
When did Precede Biosciences last raise funding?
Precede Biosciences' most recent funding round on record is a Series B of $63.5M, announced in Jan 2026.
Who is the CEO of Precede Biosciences?
Rehan Verjee is listed as CEO at Precede Biosciences.
Where is Precede Biosciences headquartered?
Precede Biosciences is based in Boston, Massachusetts, United States.
How many employees does Precede Biosciences have?
Precede Biosciences is in the 11-50 employee band.
How does Precede Biosciences' funding compare to other Biotechnology startups?
Precede Biosciences' latest round of $63.5M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,182 tracked companies over the last two years.
About FundedIQ's Precede Biosciences Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Precede Biosciences is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.